Results 81 to 90 of about 939 (187)
The Journal of Headache and PainObjective To compare the outcomes associated with the use of lasmiditan, rimegepant, ubrogepant, and zavegepant for the acute management of migraine headaches.
Xinxin Deng +11 more
doaj +1 more source
Ubrogepant: The First Gepant to Pass Food and Drug Administration for Acute Migraine
Journal of Pharmacology and Pharmacotherapeutics, 2020 Migraine is one of the most common and disabling forms of primary headache disorders. It is characterized by the presence of unilateral pulsatile headache associated commonly with nausea, vomiting, photophobia, and phonophobia lasting for about 4–72 h. Currently, nonsteroidal anti-inflammatory drugs, ergot alkaloids, and triptans are the most commonly ...
Sivagourounadin Kiruthika +1 more
openaire +1 more source
Chronic Pain: Epidemiology, Pathophysiology, and Clinical Management
MedComm, Volume 7, Issue 5, May 2026.The multidimensional nature of chronic pain is illustrated through four interconnected domains. (Left) Epidemiology and Global Burden: Chronic pain affects approximately one in five individuals globally, contributing to a rising trend in disability‐adjusted life years (YLDs) and a significant socioeconomic impact.
Zhihao Shang +12 more
wiley +1 more source
, 2020 PURPOSE OF REVIEW: Migraine is the second leading cause of years lived with disability after back pain. Poor tolerability, contraindications, drug-drug interactions and efficacy limited to a subpopulation make new approaches necessary for the acute and ...
Goadsby, Peter J.; id_orcid +2 more
core +1 more source
Pharmacokinetics of Ubrogepant in Healthy Japanese and White Adults
Clinical Pharmacology in Drug DevelopmentAbstractUbrogepant is a calcitonin gene‐related peptide receptor antagonist indicated for the acute treatment of migraine with or without aura in adults. The objectives of this study were to evaluate (1) single‐dose pharmacokinetics (PK) and dose proportionality of ubrogepant in Japanese participants, (2) the safety and tolerability of ubrogepant in ...
Ramesh, Boinpally, Joel, Trugman
openaire +2 more sources
Headache: The Journal of Head and Face Pain, Volume 66, Issue 5, Page 1181-1192, May 2026.Abstract Objective To highlight key factors required to optimize multi‐mechanistic approaches with oral combination treatments for the acute management of a migraine attack. Background Given the complex multi‐factorial nature of migraine, combining treatments with different mechanisms of action should improve outcomes compared to monotherapies, but ...
Stephen Silberstein, Alan M. Rapoport
wiley +1 more source
, 2021 Die Migräne ist eine häufige und stark beeinträchtigende neurologische Erkrankung. Sie kann mit Kopfschmerzen, einer Aura und bestimmten Begleitsymptomen einhergehen.
Wirth, Lea Undine
core +2 more sources
, 2019 Background: Research has indicated that calcitonin gene-related peptide (CGRP) receptor antagonists can be effective in the acute treatment of migraine. Six major drugs are included within this category: telcagepant, olcegepant, BI 44370, rimegepant (BMS-
Fang Xu (138747), Wenjun Sun (446555)
core +1 more source
Headache: The Journal of Head and Face Pain, Volume 66, Issue 4, Page 835-845, April 2026.Abstract Objective The primary objective of this study was to evaluate opioid and barbiturate utilization before and after the first prescription of the calcitonin gene–related peptide receptor antagonist rimegepant in individuals with migraine. Background Although not recommended in migraine treatment guidelines, opioids and barbiturates are often ...
Noah Rosen +6 more
wiley +1 more source
, 2019 Background: Research has indicated that calcitonin gene-related peptide (CGRP) receptor antagonists can be effective in the acute treatment of migraine. Six major drugs are included within this category: telcagepant, olcegepant, BI 44370, rimegepant (BMS-
Fang Xu (138747), Wenjun Sun (446555)
core +1 more source